Atossa Therapeutics
ATOS

$1.47

2.13%

Market Cap: 185M

About: Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.

Employees: 10

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,702 funds

0

Analysts bullish %

of 6 analysts

0

News positive %

of 7 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

360% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 5

146% more call options, than puts

Call options by funds: $480K | Put options by funds: $195K

146% more capital invested

Capital invested by funds: $14.1M [Q4 2023] → $34.6M (+$20.5M) [Q1 2024]

40% more repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 10

38% more funds holding

Funds holding: 47 [Q4 2023] → 65 (+18) [Q1 2024]

2.62% more ownership

Funds ownership: 12.74% [Q4 2023] → 15.36% (+2.62%) [Q1 2024]

See Fund Rankings

Research analyst outlook

6 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target

$4

172%

upside

Avg. target

$5.04

243%

upside

High target

$6.25

325%

upside

6 analyst ratings

6 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co. Emily Bodnar	308%upside $6	Buy Reiterated	28 Jun 2024
Ascendiant Capital Edward Woo	325%upside $6.25	Buy Maintained	6 Jun 2024
HC Wainwright & Co. Emily Bodnar	308%upside $6	Buy Maintained	13 May 2024
HC Wainwright & Co. Emily Bodnar	172%upside $4	Buy Reiterated	16 Apr 2024
HC Wainwright & Co. Emily Bodnar	172%upside $4	Buy Maintained	2 Apr 2024

See Analyst Rankings

Financial journalist opinion

Based on 7 articles about ATOS published over the past 30 days

Atossa Therapeutics Completes Enrollment of 80mg Pharmacokinetic Run-In Cohort in Phase 2 EVANGELINE Clinical Trial Evaluating (Z)-Endoxifen as a Neoadjuvant Treatment for ER+ / HER2- Breast Cancer

SEATTLE, July 22, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced that the 12-patient 80mg pharmacokinetic (PK) run-in cohort of the Phase 2 EVANGELINE (Endoxifen Versus exemestANe GosEreLIn) study has fully enrolled. EVANGELINE is a randomized non-inferiority trial of Atossa's patented Selective Estrogen Receptor Modulator (SERM), (Z)-endoxifen, and exemestane plus goserelin as a neoadjuvant treatment for pre-menopausal women with Grade 1 or 2 Estrogen Receptor positive (ER+) / Human Epidermal Growth Factor Receptor 2 negative (HER2-) breast cancer. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer.

Atossa Therapeutics Completes Enrollment of 80mg Pharmacokinetic Run-In Cohort in Phase 2 EVANGELINE Clinical Trial Evaluating (Z)-Endoxifen as a Neoadjuvant Treatment for ER+ / HER2- Breast Cancer

Zacks Investment Research

Are Medical Stocks Lagging Atossa Genetics (ATOS) This Year?

Here is how Atossa Genetics Inc. (ATOS) and Hologic (HOLX) have performed compared to their sector so far this year.

Are Medical Stocks Lagging Atossa Genetics (ATOS) This Year?

3 Dirt-Cheap Drug Developers With Blockbuster Potential

One of the more exciting yet admittedly risky types of investing is buying into cheap drug developer stocks early in their company life cycle. That's because the world of drug development and biotech research tends to rely on big market-moving moments like regulatory approvals and clinical trial results.

3 Dirt-Cheap Drug Developers With Blockbuster Potential

3 Penny Stock Moonshots with 300%+ Upside Potential by 2025

By now, you're well aware of the dangers of trading penny stocks with upside. But as a reminder, not only will you find a disclaimer at the tail-end of this article about penny stock dangers, but here's what the U.S. SEC says: “ Penny stocks may trade infrequently — which means that it may be difficult to sell penny stock shares once you have them.

3 Penny Stock Moonshots with 300%+ Upside Potential by 2025

Proactive Investors

Atossa Therapeutics names Heather Rees as CFO

Atossa Therapeutics Inc (NASDAQ:ATOS) has appointed Heather Rees as its new Chief Financial Officer (CFO). The move marks a promotion for Rees, who previously served as the company's senior vice president of finance and principal accounting officer.

Atossa Therapeutics names Heather Rees as CFO

Atossa Therapeutics Appoints Heather Rees as Chief Financial Officer

SEATTLE, July 02, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced the appointment of Heather Rees as the Company's new Chief Financial Officer (CFO). Ms. Rees most recently served as Atossa's Senior Vice President of Finance and Principal Accounting Officer. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer.

Atossa Therapeutics Appoints Heather Rees as Chief Financial Officer

Atossa Therapeutics Announces Updated Protocol for Clinical Trial Evaluating (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer

SEATTLE, June 28, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced protocol changes in the previously initiated study to evaluate Atossa's proprietary (Z)-endoxifen in combination with abemaciclib (VERZENIO®), a cyclin-dependent kinase (CDK) 4/6 inhibitor marketed by Eli Lilly and Company. The study is investigating the combination as a neoadjuvant treatment in women with newly diagnosed Estrogen Receptor positive (ER+) / Human Epidermal Growth Factor Receptor 2 negative (HER2-) breast cancer. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer.

Atossa Therapeutics Announces Updated Protocol for Clinical Trial Evaluating (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer

Atossa Set to Join Russell 3000® Index Effective June 28, 2024

SEATTLE, June 17, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced its expected upcoming inclusion in the Russell 3000® Index, according to preliminary Russell reconstruction information posted on the FTSE Russell website. The newly reconstructed index will take effect after the market closes on June 28, 2024. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer.

Atossa Set to Join Russell 3000® Index Effective June 28, 2024

Meme Mania Meets Medicine: 3 Biotech Stocks Primed to Soar

In a meme frenzy, any positive news related to a company has a magnified impact on the stock price. In the euphoria of 2021, companies with ambitious growth plans skyrocketed.

Meme Mania Meets Medicine: 3 Biotech Stocks Primed to Soar

Zacks Investment Research

Is Atossa Genetics (ATOS) Stock Outpacing Its Medical Peers This Year?

Here is how Atossa Genetics Inc. (ATOS) and Ocugen (OCGN) have performed compared to their sector so far this year.

Is Atossa Genetics (ATOS) Stock Outpacing Its Medical Peers This Year?

See News Rankings